Arjun Agarwal Sells 9,999 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the transaction, the senior vice president owned 15,312 shares in the company, valued at $1,295,854.56. This represents a 39.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total value of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $87.47 on Wednesday. The company has a market capitalization of $5.28 billion, a P/E ratio of -45.09 and a beta of -0.35. Oruka Therapeutics, Inc. has a one year low of $12.84 and a one year high of $97.78. The stock has a 50-day moving average price of $71.24 and a 200 day moving average price of $52.26.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Barclays boosted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings cut shares of Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Hedge Funds Weigh In On Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $37,000. PNC Financial Services Group Inc. acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $39,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Oruka Therapeutics during the 4th quarter valued at about $67,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics during the third quarter worth about $43,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.